Clinical Trial Update: A Study To Investigate The Effect Of PD-217,014 On Abdominal Pain/Discomfort In Patients With IBS. [Phase 2]

View source ↗

Summary

A Pfizer-sponsored Phase 2 clinical trial (PD-217,014) evaluating abdominal pain in irritable bowel syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• PD-217,014

Snippet

Sponsor: Pfizer | Conditions: Irritable Bowel Syndrome | Phase 2 | Status: COMPLETED